Toute la journée
Public ciblé : PME, grandes entreprises, centres de recherche…
L’Initiative Technologique Conjointe IMI2 a publié son 15e appel à propositions.
8 sujets sont ouverts (soumission en 2 étapes) :
- Integrated research platforms enabling patient-centric drug development
- Blockchain Enabled Healthcare
- Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
- Emerging translational safety technologies and tools for interrogating human immuno-biology
- Development and validation of translational platforms in support of synaptopathy drug discovery
- Digital endpoints in neurodegenerative and immune-mediated diseases
- AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
- AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic.